It has been demonstrated that intratumoral STING agonist therapy can activate type I IFN signaling and can induce the upregulation of vascular normalizing genes in Lewis lung carcinoma (LLC) models, such as angiopoietin 1 (ANGPT1), platelet-derived growth factor receptor beta (PDGFRB), melanoma cell adhesion molecule (MCAM) and cadherin 5 (CDH5). Here, ANGPT1 is linked to Carcinoma, Lewis Lung.